Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tiago Torres

Showing results (211-220 of 274) with videos related to

Pageof 28
Sort By:
Drugs in Context|January 17, 2022
Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patientsTiago Torres, Margarida Gonçalo, Maria João Paiva Lopes, et al.
Journal of Toxicology and Environmental Health. Part A|June 20, 2015
Effects of Tributyltin and Other Retinoid Receptor Agonists in Reproductive-Related Endpoints in the Zebrafish (Danio rerio)Daniela Lima, L Filipe C Castro, Inês Coelho, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 12, 2024
Approved systemic drugs needed for dermatosis like alopecia areata, hidradenitis and vitiligo: A SPIN-FRT evaluationPhyllis Spuls, Antonios Kolios, Marlide Jukema, et al.
European Journal of Dermatology : EJD|June 29, 2018
The DRAGON study: biologic DRug survivAl in PortuGuese psOriasis patieNtsTiago Torres, Paulo Filipe, Artur Sousa Basto, et al.
Advances in Therapy|December 14, 2022
Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World SettingCharles Lynde, Elisabeth Riedl, Julia-Tatjana Maul, et al.
Clinical Drug Investigation|December 19, 2023
Real-World Effectiveness and Safety of Baricitinib in Patients with Atopic DermatitisEgídio Freitas, Maria João Paiva Lopes, Maria João Cruz, et al.
Dermatology and Therapy|June 26, 2024
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic DermatitisPeter A Lio, April Armstrong, Jan Gutermuth, et al.
Dermatology and Therapy|November 10, 2025
Real-World Evidence on Dose Spacing of Risankizumab for Psoriasis: A Multicenter Retrospective Cohort StudyMartim Luz, Ana Luísa João, Pedro Mendes-Bastos, et al.
American Journal of Clinical Dermatology|May 24, 2025
Real-World Effectiveness, Safety, and Drug Survival of Risankizumab in Adult Patients with Plaque Psoriasis: A 3-Year Multicenter Retrospective Cohort StudyTiago Torres, Ana Luísa João, Martim Luz, et al.
Dermatology and Therapy|August 17, 2024
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical TrialLuis Puig, Antonio Costanzo, Elke M G J de Jong, et al.
Pageof 28

Showing results (211-220 of 274) with videos related to

Sort By:
Pageof 28
Drugs in Context|January 17, 2022
Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patientsTiago Torres, Margarida Gonçalo, Maria João Paiva Lopes, et al.
Journal of Toxicology and Environmental Health. Part A|June 20, 2015
Effects of Tributyltin and Other Retinoid Receptor Agonists in Reproductive-Related Endpoints in the Zebrafish (Danio rerio)Daniela Lima, L Filipe C Castro, Inês Coelho, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 12, 2024
Approved systemic drugs needed for dermatosis like alopecia areata, hidradenitis and vitiligo: A SPIN-FRT evaluationPhyllis Spuls, Antonios Kolios, Marlide Jukema, et al.
European Journal of Dermatology : EJD|June 29, 2018
The DRAGON study: biologic DRug survivAl in PortuGuese psOriasis patieNtsTiago Torres, Paulo Filipe, Artur Sousa Basto, et al.
Advances in Therapy|December 14, 2022
Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World SettingCharles Lynde, Elisabeth Riedl, Julia-Tatjana Maul, et al.
Clinical Drug Investigation|December 19, 2023
Real-World Effectiveness and Safety of Baricitinib in Patients with Atopic DermatitisEgídio Freitas, Maria João Paiva Lopes, Maria João Cruz, et al.
Dermatology and Therapy|June 26, 2024
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic DermatitisPeter A Lio, April Armstrong, Jan Gutermuth, et al.
Dermatology and Therapy|November 10, 2025
Real-World Evidence on Dose Spacing of Risankizumab for Psoriasis: A Multicenter Retrospective Cohort StudyMartim Luz, Ana Luísa João, Pedro Mendes-Bastos, et al.
American Journal of Clinical Dermatology|May 24, 2025
Real-World Effectiveness, Safety, and Drug Survival of Risankizumab in Adult Patients with Plaque Psoriasis: A 3-Year Multicenter Retrospective Cohort StudyTiago Torres, Ana Luísa João, Martim Luz, et al.
Dermatology and Therapy|August 17, 2024
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical TrialLuis Puig, Antonio Costanzo, Elke M G J de Jong, et al.
Pageof 28